Valneva Launches 60M Euro Share Placement for Vaccine Development
Company Announcements

Valneva Launches 60M Euro Share Placement for Vaccine Development

Valneva (VALN) has released an update.

Valneva SE is initiating a private placement of approximately 60 million euros worth of new ordinary shares to fund its vaccine development programs, including clinical trials for chikungunya, Shigella, and Zika vaccines, and to further commercialize its chikungunya vaccine IXCHIQ®. The company is offering the shares at a discounted price and expects to use the proceeds to support its growth and operational business until milestone revenues from its Lyme disease program contribute to profitability. This financing strategy is aimed at strengthening Valneva’s financial position as it advances its pipeline of vaccine candidates.

For further insights into VALN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskValneva SE Reports Profitable Nine-Month Performance
TipRanks Auto-Generated NewsdeskValneva Reports Profitable Quarter Amid Vaccine Launches
TipRanks Auto-Generated NewsdeskValneva’s Chikungunya Vaccine Gains Scientific Spotlight
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App